Parkinson DiseasePD FrontlineNCT06151002
PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's
An observational study of Parkinson Disease, run by University College, London at 1 site in United Kingdom.
Trial summary
PD Frontline (part of RAPSODI GD) is an online study observational study for People with Parkinson's. The aims are to better understand the genetic nature of Parkinson's and to connect participants to clinical trials and studies, particularly those with a genetic focus. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Parkinson Disease
- How many people
- 20,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 15 Feb 2020to 20 Aug 2040
- How long will I take part?
- 20 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Adult, Older adult
Study population: Randomly selected population, recruited via established NHS sites and self-referral to the website.
Who may be able to join
- Formal diagnosis of Parkinson Disease
Who cannot join
- Confirmation that the individual carries a GBA1 variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
- History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)
- Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.
- Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
University College London (UCL)
London, NW3 2PF
Georgie Pittwood, 020 8016 8413, g.pittwood@ucl.ac.uk
PD Frontline Team, pdfrontline@ucl.ac.uk
About this study
Official title: PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's
PD Frontline (part of RAPSODI GD) is an online study observational study for People with Parkinson's. The aims are to better understand the genetic nature of Parkinson's and to connect participants to clinical trials and studies, particularly those with a genetic focus.
To do this, participants are offered genetic sequencing for two common genetic risk factors for Parkinson's Disease, the GBA1 and LRRK2 gene, with an at-home sample collection kit. Return postage is free.
Read the detailed description
PD Frontline is an online one-time questionnaire based study with the purpose of identifying potential candidates for gene targeted trials and observational studies. The study also seeks to better characterise GBA1 risk factors for Parkinson's Disease.
Once the questionnaire is completed, the participant is sent a sample collection kit in the post for use in genetic testing. The genes tested for are GBA1, the most common risk factor gene for Parkinson's, and LRRK2.
Once tested and where consent is in place, the participant is informed of their results and kept up-to-date with any studies or trials for which they may be eligible. Individuals identified to have genetic variants are contacted by the team to discuss, all participants are sent a report via their study profile.
Participants are kept up-to-date with any study outcomes via newsletters.
- Conditions
- Parkinson Disease
- Keywords
- GBA1, LRRK2, Parkinson's, PD, Parkinson, genetic
- Medical subject headings
- Parkinson Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Genotype of participants
The primary outcome of the study is to genotype the GBA1 gene, obtained with Oxford Nanopore long read sequencing.
Measured: 20 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Nov 2023
- Study start15 Feb 2020
- Primary completion1 Jan 2028 (estimated)
- Study completion20 Aug 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 20,000 participants (estimated)
- Target duration
- 20 Years
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research, Cure Parkinson's
- Responsible party
- Principal investigator, Anthony Schapira, University College, London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06151002
- Sponsor's protocol ID
- 173275
- Acronym
- PD Frontline
- Status last verified
- Oct 2026
- First submitted
- 11 Oct 2023
- Last updated
- 29 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's
- ClinicalTrials.gov ID
- NCT06151002
- Acronym / sponsor ID
- PD Frontline / 173275
- Conditions
- Parkinson Disease
- Keywords
- GBA1, LRRK2, Parkinson's, PD, Parkinson, genetic
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20,000 participants (estimated)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research, Cure Parkinson's
- Study start
- 15 Feb 2020 (actual)
- Primary completion
- 1 Jan 2028 (estimated)
- Study completion
- 20 Aug 2040 (estimated)
- First posted
- 30 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PD Frontline (part of RAPSODI GD) is an online study observational study for People with Parkinson's. The aims are to better understand the genetic nature of Parkinson's and to connect participants to clinical trials and studies, particularly those with a genetic focus.
To do this, participants are offered genetic sequencing for two common genetic risk factors for Parkinson's Disease, the GBA1 and LRRK2 gene, with an at-home sample collection kit. Return postage is free.
Detailed description
PD Frontline is an online one-time questionnaire based study with the purpose of identifying potential candidates for gene targeted trials and observational studies. The study also seeks to better characterise GBA1 risk factors for Parkinson's Disease.
Once the questionnaire is completed, the participant is sent a sample collection kit in the post for use in genetic testing. The genes tested for are GBA1, the most common risk factor gene for Parkinson's, and LRRK2.
Once tested and where consent is in place, the participant is informed of their results and kept up-to-date with any studies or trials for which they may be eligible. Individuals identified to have genetic variants are contacted by the team to discuss, all participants are sent a report via their study profile.
Participants are kept up-to-date with any study outcomes via newsletters.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 20 Years
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Randomly selected population, recruited via established NHS sites and self-referral to the website.
Key inclusion criteria (1 listed)
- Formal diagnosis of Parkinson Disease
Key exclusion criteria (4 listed)
- Confirmation that the individual carries a GBA1 variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
- History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)
- Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.
- Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Genotype of participants
Time frame: 20 years
The primary outcome of the study is to genotype the GBA1 gene, obtained with Oxford Nanopore long read sequencing.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
- Study WebsiteLink provided by the sponsor.
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by University College, London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact PD Frontline Team (020 8016 8413, pdfrontline@ucl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Genotype of participants (time frame: 20 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.